12 withdrawn, 1 recruiting, 1 terminated. 14 Phase 2, 10 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Withdrawn 12, Recruiting 1, Terminated 1 |
| Phase 1 | 10 | Withdrawn 9, Terminated 1 |
Follow haNK: new trials by email Literature Review of haNK trials Research Report on haNK
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine Aldoxorubicin Hydrochloride, ALT-803, ETBX-011 - Colorectal Cancer Metastatic, mCRC | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 2 | 2018-09-28 | 2024-12-11 |
| QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine Leucovorin, 5-Fluorouracil, Aldoxorubicin HCl - Triple Negative Breast Cancer (TNBC) | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-09-01 | 2025-02-21 | |
| QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. Aldoxorubicin Hydrochloride, ALT-803, ETBX-051 - Chordoma, Unresectable Malignant Neoplasm | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-08-31 | 2025-02-21 | |
| QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC avelumab, bevacizumab, capecitabine - Colorectal Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-08-01 | 2025-02-21 | |
| QUILT-3.088: NANT Pancreatic Cancer Vaccine Gemcitabine, Nab-paclitaxel, Aldoxorubicin HCl - Metastatic Pancreatic Cancer | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-08-01 | 2025-02-21 | |
| QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Nab-paclitaxel, Cisplatin, 5Fluorouracil - Non Small Cell Lung Cancer | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-06-01 | 2025-02-21 | |
| QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors avelumab, Bevacizumab, Capecitabine - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-02-01 | 2025-02-21 | |
| QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy avelumab, bevacizumab, capecitabine - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy Avelumab, Bevacizumab, Capecitabine - Melanoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy Avelumab, Bevacizumab, Capecitabine - Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-24 | |
| QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL avelumab, bevacizumab, capecitabine - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-24 | |
| QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy Avelumab, Bevacizumab, Capecitabine - Merkel Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy avelumab, bevacizumab, capecitabine - Urothelial Carcinoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| Personalized NK Cell Therapy in CBT Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2016-05-19 | 2026-11-02 |
Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Lymphoma, Non-Hodgkin (2) · Triple Negative Breast Neoplasms (2) · Anemia, Refractory, with Excess of Blasts (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Transitional Cell (1) · Chordoma (1) · Hodgkin Disease (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myeloid, Chronic-Phase (1) · Leukemia, Myelomonocytic, Chronic (1) · Melanoma (1)
ImmunityBio, Inc. (13) · M.D. Anderson Cancer Center (1)
United States (6)
R01CA211044 (1)